Interleukin-25 Mediates Transcriptional Control of PD-L1 via STAT3 in Multipotent Human Mesenchymal Stromal Cells (hMSCs) to Suppress Th17 Responses
Open accessThe DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.
Abstract
Multipotent human mesenchymal stromal cells (hMSCs) harbor immunomodulatory properties that are therapeutically relevant. One of the most clinically important populations of leukocytes is the interleukin-17A (IL-17A)-secreting T (Th17) lymphocytes. However, mechanisms of hMSC and Th17 cell interactions are incompletely resolved. We found that, along with Th1 responses, hMSCs strongly suppressed Th17 responses and this required both IL-25--also known as IL--17E-as well as programmed death ligand-1 (PD-L1), a potent cell surface ligand for tolerance induction. Knockdown of IL-25 expression in hMSCs abrogated Th17 suppression in vitro and in vivo. However, IL-25 alone was insufficient to significantly suppress Th17 responses, which also required surface PD-L1 expression. Critically, IL-25 upregulated PD-L1 surface expression through the signaling pathways of JNK and STAT3, with STAT3 found to constitutively occupy the proximal region of the PD-L1 promoter. Our findings demonstrate the complexities of hMSC-mediated Th17 suppression, and highlight the IL-25/STAT3/PD-L1 axis as a candidate therapeutic target.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Human mesenchymal stem cells modulate allogeneic immune cell responses
Aggarwal, S., & Pittenger, M. F. (2005) · Blood · doi:10.1182/blood-2004-04-1559 · Cited by 4,511
Di Nicola, M., Carlo-Stella, C., Magni, M., Milanesi, M., Longoni, P. D., Matteucci, P., Grisanti, S., & Gianni, A. M. (2002) · Blood · doi:10.1182/blood.v99.10.3838 · Cited by 3,226
Phenotypic and functional features of human Th17 cells
Annunziato, F., Cosmi, L., Santarlasci, V., Maggi, L., Liotta, F., Mazzinghi, B., Parente, E., Filì, L., Ferri, S., Frosali, F., et al. (2007) · The Journal of Experimental Medicine · doi:10.1084/jem.20070663 · Cited by 1,861 · cited 2×
“…natural Tregs in PBLs and CD4 cells was increased (Figures S1E and S1F). hMSCs not only suppress IL-17A cells, but also prominently suppress IL17A/IFN-g double producer cells, which are the dominant subtype of Th17 cells at inflammatory sites (Annunziato et al., 2007; Zielinski et al., 2012).”
BackgroundCaplan, A. I., & Correa, D. (2011) · Cell Stem Cell · doi:10.1016/j.stem.2011.06.008 · Cited by 1,682
Targeting IL-17 and TH17 cells in chronic inflammation
Miossec, P., & Kolls, J. K. (2012) · Nature Reviews Drug Discovery · doi:10.1038/nrd3794 · Cited by 1,414 · cited 4×
“Known also as Th17 cells, this T helper cell subpopulation is important in mediating host responses toward microbial infections, as well as participating in the pathogenesis of many autoimmune and chronic inflammatory diseases that had been long believed to be caused by Th1 cells (Miossec and Kolls, 2012).”
BackgroundInfluentialFunctional Specialization of Interleukin-17 Family Members
Iwakura, Y., Ishigame, H., Saijo, S., & Nakae, S. (2011) · Immunity · doi:10.1016/j.immuni.2011.02.012 · Cited by 1,289
TH17 cells in development: an updated view of their molecular identity and genetic programming
Dong, C. (2008) · Nature reviews. Immunology · doi:10.1038/nri2295 · Cited by 1,064 · cited 4×
“(I and J) IL-22 production in four donors of CD3+ CD4 T cells (I, representative data; J, pooled data) without and with co-culture of two donors of hMSCs (donors A and B) was assessed by intracellular staining.”
BackgroundInfluentialBrown, J. A., Dorfman, D. M., Ma, F.-R., Sullivan, E. L., Munoz, O., Wood, C. R., Greenfield, E. A., & Freeman, G. J. (2003) · The Journal of Immunology · doi:10.4049/jimmunol.170.3.1257 · Cited by 968 · cited 2×
“…Responses by Upregulating Surface Expression of PD-L1 It has been reported that PD-L1 ligand, which is constitutively expressed on hMSC cell surfaces (Chang et al., 2006; Stagg et al., 2006), is a strong inhibitor of IL-17A production in human T cells (Brown et al., 2003; Hirahara et al., 2012).”
BackgroundPathogen-induced human TH17 cells produce IFN-γ or IL-10 and are regulated by IL-1β
Zielinski, C. E., Mele, F., Aschenbrenner, D., Jarrossay, D., Ronchi, F., Gattorno, M., Monticelli, S., Lanzavecchia, A., & Sallusto, F. (2012) · Nature · doi:10.1038/nature10957 · Cited by 919
IL-25 regulates Th17 function in autoimmune inflammation
Kleinschek, M. A., Owyang, A. M., Joyce-Shaikh, B., Langrish, C. L., Chen, Y., Gorman, D. M., Blumenschein, W. M., McClanahan, T., Brombacher, F., Hurst, S. D., et al. (2007) · The Journal of Experimental Medicine · doi:10.1084/jem.20061738 · Cited by 396 · cited 1×
“Surprisingly, MS/MS studies revealed that IL-25, also known as IL17E and a potent suppressor of Th17 responses (Kleinschek et al., 2007; Zaph et al., 2008), was highly secreted by hMSCs.”
Background
Cited by
Role of the tumor microenvironment in PD-L1/PD-1-mediated tumor immune escape
Jiang, X., Wang, J., Deng, X., Xiong, F., Ge, J., Xiang, B., Wu, X., Ma, J., Zhou, M., Li, X., et al. (2019) · Molecular Cancer · doi:10.1186/s12943-018-0928-4 · Cited by 1,457
Mesenchymal Stem Cell Immunomodulation: Mechanisms and Therapeutic Potential
Song, N., Scholtemeijer, M., & Shah, K. (2020) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2020.06.009 · Cited by 948
Oncogenic activation of the STAT3 pathway drives PD-L1 expression in natural killer/T-cell lymphoma
Song, T. L., Nairismägi, M.-L., Laurensia, Y., Lim, J.-Q., Tan, J., Li, Z.-M., Pang, W.-L., Kizhakeyil, A., Wijaya, G.-C., Huang, D.-C., et al. (2018) · Blood · doi:10.1182/blood-2018-01-829424 · Cited by 326
Sasidharan Nair, V., Toor, S. M., Ali, B. R., & Elkord, E. (2018) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2018.1471137 · Cited by 159
“The sequences of primers are as previously described [22].”
MethodSignal transducer and activator of transcription 3 signaling in tumor immune evasion
Zhang, L., Kuca, K., You, L., Zhao, Y., Musilek, K., Nepovimova, E., Wu, Q., Wu, W., & Adam, V. (2022) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2021.107969 · Cited by 67
Mesenchymal stem cell therapy as a game-changer in liver diseases: review of current clinical trials
Huang, W.-C., Li, Y.-C., Chen, P.-X., Ma, K. S.-K., & Wang, L.-T. (2025) · Stem Cell Research & Therapy · doi:10.1186/s13287-024-04127-y · Cited by 29
Self-citation
Metadata
- Authors
- Wang, W.-B., Yen, M.-L., Liu, K.-J., Hsu, P.-J., Lin, M.-H., Chen, P.-M., Sudhir, P.-R., Chen, C.-H., Chen, C.-H., Sytwu, H.-K., & Yen, B. L.
- Venue
- Stem Cell Reports
- Publisher
- Elsevier BV
- Published
- 2015-09
- Volume
- 5
- Issue
- 3
- Pages
- 392-404
- ISSN
- 2213-6711 (ISSN-L)
- OpenAlex
- W1915829159
- Cited by
- 81
- References
- 12
- FWCI
- 4.57
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.